Insider · CIK 0001717972
David Lemus
Files at SLN (Silence Therapeutics plc), SCLX (Scilex Holding Co). First filing Oct 18, 2024, latest Oct 18, 2024.
David Lemus files SEC Form 4 as director at SCLX (Scilex Holding Co), and also at SLN (Silence Therapeutics plc). Since Oct 18, 2024, David Lemus has reported 1 open-market buy worth $1,800 and 0 open-market sells worth $0, the latest filed on Oct 18, 2024.
A track record needs three past buys with six months of prices behind them; David Lemus has 0, so none is measured yet.
The newest scored trade: bought $1,800 of SCLX on Oct 17, 2024, filed Oct 18, 2024, scored 38 (weak).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
SCLX: Scilex Holding Co
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 2, 2026 | SLN Silence Therapeutics plc | AGrant or award Share Option (Right to Buy)derivative | +90,000 | $0.00 | $0 | 90,000 | Jan 6, 2026 |
| Oct 17, 2024 | SCLX Scilex Holding Co | POpen-market purchase Common Stock | +2,000 | $0.90 | $1,800 | 2,000 | Oct 18, 2024 |
Questions about David Lemus
Answered from the filings on this page, as of the latest one.
Is David Lemus buying or selling?
Not in the last 12 months. David Lemus's latest open-market trade on SEC Form 4 was bought $1,800 of SCLX on Oct 17, 2024.
How did David Lemus's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and David Lemus has 0.
Where does David Lemus file Form 4?
David Lemus has filed Form 4 at SCLX (Scilex Holding Co); SLN (Silence Therapeutics plc). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.